Darifenacin
As of the edition of 20 October 2026, Darifenacin is a small molecule: marketed, first approved in 2004 (EU); acts on CHRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2004
- Kind
- Small molecule
- Brand name
- Enablex
- First approved
- 22 October 2004 (EU)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- AbbVie; 2 holders in all
- Registered trials
- 22, 3 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Nervous system; Immune system; Inherited and neonatal; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Darifenacin.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 5 | 5 | 0 | 0 |
| Phase 1 | 4 | 2 | 0 | 0 |
| Phase 2 | 5 | 2 | 1 | 2 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 5 | 4 | 0 | 1 |
| All trials | 22 |